Tested repeat injections for frequent genital herpes outbreaks
Part of Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether repeat doses of UB-621 can make frequent genital herpes outbreaks safer and less frequent. It may help people who have HSV-2 and many recurrences each year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign consent
- Your screening blood test shows HSV-2 (genital herpes)
- You had 6 to 12 genital herpes outbreaks in the past year
- You have a new sore and can get to the clinic within 72 hours
- You can keep a daily outbreak diary during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new mRNA vaccine designed to protect against herpes simplex virus type 2 (HSV-2), the virus that causes genital herpes. It is for healthy adults who have not had a genital herpes outbreak in the last 6 months.
This trial tests whether a medicine called acyclovir can prevent herpes simplex outbreaks in people who also have an autoimmune rheumatic disease. It may help reduce the number of painful cold sores or genital herpes episodes you experience.
This trial tests whether 2LHERP® can reduce or manage frequent herpes infections around the mouth. It compares the study drug to a placebo (inactive treatment) in people who get many episodes each year.
This Phase 3 study tests UB-421 added to a customized (optimized) set of existing HIV medicines for people with HIV that is resistant to multiple drugs. It may help reduce the virus more effectively when standard treatments have not been enough.
This trial tests a new drug, VG2025, given through a vein for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the tumors.
This Phase 1 trial tests the safety and early effects of VG2025 in people with advanced solid cancers that have stopped responding to standard treatments. It’s mainly looking for side effects and how the body processes the drug, and it may offer a new option when other treatments haven’t worked.
Hear when a new Recurrent Genital Herpes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.